Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR2285 with Antiplatelets in Healthy Subjects
NCT04945616Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of shr2285 in thrombosis (3 arms), sponsored by Hengrui. Primary endpoint: Number of subjects with adverse events and severity of adverse events. Started Jul 2021; status: completed.
02
Drugs
shr2285
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04945616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945616.